These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 29204840)
1. Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis. Kline C; Felton E; Allen IE; Tahir P; Mueller S J Neurooncol; 2018 Mar; 137(1):103-110. PubMed ID: 29204840 [TBL] [Abstract][Full Text] [Related]
2. Subventricular zone involvement at recurrence is a strong predictive factor of outcome following high grade glioma reirradiation. Attal J; Chaltiel L; Lubrano V; Sol JC; Lanaspeze C; Vieillevigne L; Latorzeff I; Cohen-Jonathan Moyal E J Neurooncol; 2018 Jan; 136(2):413-419. PubMed ID: 29273890 [TBL] [Abstract][Full Text] [Related]
3. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients. Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134 [TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy for high-grade glioma. Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542 [TBL] [Abstract][Full Text] [Related]
5. A systematic review and meta-analysis of outcomes in pediatric, recurrent ependymoma. Byer L; Kline CN; Coleman C; Allen IE; Whitaker E; Mueller S J Neurooncol; 2019 Sep; 144(3):445-452. PubMed ID: 31502040 [TBL] [Abstract][Full Text] [Related]
6. Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better. Palmer JD; Siglin J; Yamoah K; Dan T; Champ CE; Bar-Ad V; Werner-Wasik M; Evans JJ; Kim L; Glass J; Farrell C; Andrews DW; Shi W J Neurooncol; 2015 Sep; 124(2):215-21. PubMed ID: 26024653 [TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. Ji N; Weng D; Liu C; Gu Z; Chen S; Guo Y; Fan Z; Wang X; Chen J; Zhao Y; Zhou J; Wang J; Ma D; Li N Oncotarget; 2016 Jan; 7(4):4369-78. PubMed ID: 26716896 [TBL] [Abstract][Full Text] [Related]
9. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter? Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159 [TBL] [Abstract][Full Text] [Related]
10. Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study. Koo T; Lim DH; Seol HJ; Dho YS; Kim IH; Chang JH; Lee J; Jung TY; Gwak HS; Cho KH; Hong CK; Lee IJ; Kim E; Kim JH; Hong YK; Jang HS; Kim CY; Kim IA; Kim SH; Kim YI; Kim EY; Kim WC; Hong S J Neurooncol; 2018 Nov; 140(2):445-455. PubMed ID: 30097825 [TBL] [Abstract][Full Text] [Related]
11. Survival gain with re-Op/RT for recurred high-grade gliomas depends upon risk groups. Chun SJ; Park SH; Park CK; Kim JW; Kim TM; Choi SH; Lee ST; Kim IH Radiother Oncol; 2018 Aug; 128(2):254-259. PubMed ID: 29937212 [TBL] [Abstract][Full Text] [Related]
12. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. Krishnatry R; Zhukova N; Guerreiro Stucklin AS; Pole JD; Mistry M; Fried I; Ramaswamy V; Bartels U; Huang A; Laperriere N; Dirks P; Nathan PC; Greenberg M; Malkin D; Hawkins C; Bandopadhayay P; Kieran MW; Manley PE; Bouffet E; Tabori U Cancer; 2016 Apr; 122(8):1261-9. PubMed ID: 26970559 [TBL] [Abstract][Full Text] [Related]
13. Seizures at presentation are correlated with better survival outcomes in adult diffuse glioma: A systematic review and meta-analysis. Fan X; Li Y; Shan X; You G; Wu Z; Li Z; Qiao H; Jiang T Seizure; 2018 Jul; 59():16-23. PubMed ID: 29727741 [TBL] [Abstract][Full Text] [Related]
14. Effect of Treatment Modalities on Progression-Free Survival and Overall Survival in Molecularly Subtyped World Health Organization Grade II Diffuse Gliomas: A Systematic Review. Ghaffari-Rafi A; Samandouras G World Neurosurg; 2020 Jan; 133():366-380.e2. PubMed ID: 31473344 [TBL] [Abstract][Full Text] [Related]
15. Irradiation and bevacizumab in high-grade glioma retreatment settings. Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162 [TBL] [Abstract][Full Text] [Related]